Contracts › 75A50125C00017
75A50125C00017: Development of CD388 As a Long-Lasting Prophylactic Anti-Viral Option for Protection Against the Health Impacts Caused By Influenza
Awarded to Cidara Therapeutics Inc by Office of Assistant Secretary for Preparedness and Response.
$58.1Mobligated
$339.2Mpotential value
29 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50125C00017 |
|---|---|
| Awardee | Cidara Therapeutics Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN14 Health R&D Services; Health Care Services; R&D Administrative Expenses |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 30 September 2025 to 29 September 2027 |
| Potential end | 03 July 2030 |
| Estimated recompete solicitation | ~Q2 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record